Company: BDRX
Filing Date: 2025-11-24
Form Type: 424B3
Source: 0001214659-25-017136
Chunk: 18

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-24
Form: 424B3
Chunk 18
---
  
 an aggregate of 575,500,000 Ordinary Shares (in the form of Depositary Shares), and (ii)       
 Series D Warrants which entitle the selling shareholder to purchase an aggregate of 9,600,000  
 Ordinary Shares (in the form of Depositary Shares), which we are registering hereby. The       
 warrants are subject to a beneficial ownership limitation of 9.99%, which does not permit      
 the selling shareholder to exercise that portion of the warrants that would result in the      
 selling shareholder and its affiliates owning, after exercise, a number of our Ordinary Shares 
 in excess of the beneficial ownership limitation. The amounts and percentages in the table     
 do not give effect to the 9.99% beneficial ownership limitation, if applicable. The principal  
 business address of Brio Capital Master Fund Ltd. is c/o Brio Capital Management LLC, 100      
 Merrick Road, Suite 401W, Rockville Centre, NY 11570.                                          |

| (7) | The selling shareholder holds Series                                                              
 D Warrants which entitle the selling shareholder to purchase an aggregate of 9,600,000 Ordinary   
 Shares (in the form of Depositary Shares), which we are registering hereby. The warrants          
 are subject to a beneficial ownership limitation of 9.99%, which does not permit the selling      
 shareholder to exercise that portion of the warrants that would result in the selling shareholder 
 and its affiliates owning, after exercise, a number of our Ordinary Shares in excess of the       
 beneficial ownership limitation. The amounts and percentages in the table do not give effect      
 to the 9.99% beneficial ownership limitation, if applicable. The principal business address       
 of Cavalry Investment Fund LP is 82 E. Allendale Road, Suite 5B, Saddle River, NJ 07458.          |

| (8) | The selling shareholder holds (i)                                                              
 warrants issued by us in prior transactions which entitle the selling shareholder to purchase  
 an aggregate of 575,500,000 Ordinary Shares (in the form of Depositary Shares), and (ii)       
 Series D Warrants which entitle the selling shareholder to purchase an aggregate of 9,600,000  
 Ordinary Shares (in the form of Depositary Shares), which we are registering hereby. The       
 warrants are subject to a beneficial ownership limitation of 9.99%, which does not permit      
 the selling shareholder to exercise that portion of the warrants that would result in the      
 selling shareholder and its affiliates owning, after exercise